US 10342815
GLA monotherapy for use in cancer treatment
granted A61KA61K2039/505A61K31/7016
Quick answer
US patent 10342815 (GLA monotherapy for use in cancer treatment) held by IMMUNE DESIGN CORP. expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- IMMUNE DESIGN CORP.
- Grant date
- Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61K, A61K2039/505, A61K31/7016, A61K31/7024, A61K31/7028